Results 81 to 90 of about 1,537,031 (315)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Safety of anti-TNFa biological drugs

open access: yesReumatismo, 2011
To analyse TNF-α antagonists (infliximab, etanercept e adalimumab) side effects published in the literature.Review of published studies on this matter.The main side effects reported include severe infections (even though such a risk is increased per se in RA patients), possible reactivation of a previous tuberculosis, development of opportunist germs ...
Trotta F, VALENTINI, Gabriele
openaire   +6 more sources

Identifying safety strategies for on-farm grain bins using risk analysis [PDF]

open access: yes, 2002
The potential for grain bin accidents exists each year on Arkansas farms and farms across the nation. The trend toward increasing utilization of on-farm grain drying and storage could lead to an increase in grain bin accidents. The sharp contrast between
Avery, Raymond S.   +2 more
core   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Optimization of Ultrasound-assisted Extraction of Phytoglycogen from Sweet Corn and Its Bioactivity Evaluation

open access: yesShipin gongye ke-ji
The optimal extraction process of phytoglycogen (PG) from sweet corn by ultrasound-assisted method was studied, and the physicochemical properties and biological activities of PG were evaluated in this paper. The effects of solid-liquid ratio, ultrasonic
Qiang CHEN   +7 more
doaj   +1 more source

Safety evaluation of the food enzyme pullulanase from genetically modified Bacillus subtilis strain NZYM-AK [PDF]

open access: yes, 2017
Publisher ...
Aguilera-Gómez, Margarita   +29 more
core   +3 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Food safety as a public health issue for developing countries [PDF]

open access: yes
"This brief reviews the incidence and health consequences of biological pathogens in developing countries, as these are the most important food safety risks in those parts of the world, and provides an overview of possible methods of control." from ...
Kaferstein, Fritz K.
core  

Adverse reactions of biological therapies in patients with psoriasis [PDF]

open access: yes, 2017
Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp.
Georgescu, Simona R.   +5 more
core   +4 more sources

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

open access: yesMolecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy